Galectin-3 Level in Ankylosing Spondylitis Patients

Completed

• Conditions: Ankylosing Spondylitis
• Interventions: Other: Serum galectin-3 concentration was measured.

• Registration Number: NCT04746196
• Lead Sponsor: Recep Tayyip Erdogan University Training and Research Hospital

Brief Summary

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Detailed Description

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs.

We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2017-06-30
• Study Completion: 2017-08-30
• Study First Submitted: 2021-02-04
• Study First Submitted QC: 2021-02-08
• Study First Posted: 2021-02-09
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-17
• Last Update Posted: 2021-04-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Ankylosing spondylitis patients
• Healthy controls

Exclusion Criteria

• Hyperlipidemia
• Liver diseases
• Renal diseases
• Hematological diseases
• Familial thyroid diseases
• Neoplastic diseases
• Autoimmune infectious diseases
• Receiving anti-inflammatory drugs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
35 controls	Serum galectin-3 concentration was measured.	Healthy controls
45 ankylosing spondylitis patients.	Serum galectin-3 concentration was measured.	Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.

Primary Outcome Measures

Name	Time	Method
Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients	5 months	Correlation